Introduction
The increasing global prevalence of type 2 diabetes (T2D) has led 25 the scientific community to investigate different strategies in order to slow down its evolution. Dipeptidyl peptidase IV (DPP-IV) inhibitors belong to a new class of drugs with an antidiabetic action, with Sitagliptin ® (Januvia ® , Merck & Co., Inc. USA) being the first DPP-IV inhibitor launched on the market. DPP-IV 30 cleaves incretins such as glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in vivo. Inhibition of DPP-IV therefore increases the half-life of incretins, thereby promoting insulin secretion from pancreatic beta cells 1 . Food protein-derived bioactive peptides have been shown to 35 positively affect biomarkers of T2D such as post-prandial glycaemia and insulin secretion [2] [3] [4] . It is thought that the antidiabetic properties of specific food protein hydrolysates may arise from their DPP-IV inhibitory activity 5, 6 . Food protein hydrolysates, originating mostly from milk, have been reported 40 for their DPP-IV inhibitory potential 7 . The peptides therein may inhibit DPP-IV through different modes of inhibition [8] [9] [10] . In a physiological situation, it is expected that different food proteinderived peptides may concomitantly inhibit DPP-IV. However, the contribution of multiple food protein-derived peptides, as 45 present in food protein hydrolysates, to overall DPP-IV inhibition has not been determined. The combination of milk proteinderived peptides with Sitagliptin was recently shown to have an additive effect on DPP-IV inhibition 11 . However, to date the interactive effects of peptide-peptide and peptide-drug 50 combinations on DPP-IV inhibition does not appear to have been extensively studied.
The interactive effects of drug mixtures is conventionally studied using an isobole methodology 12, 13 . It has been recently proposed that using combinations of antidiabetic drugs and 55 phytochemicals may be a new approach to help reduce the sideeffects observed during drug intake 13 . Synergistic antidiabetic activity has been shown in vivo when combinations of phytochemicals (ferulic acid) and antidiabetic drugs (metformin and thiazolidinedione) were employed 14 . To our understanding, 60 the isobole method has not been previously applied to determine interactive effects between drug:peptide or binary peptide mixtures. The aim of this study was therefore to utilise an isobole methodology to study the interactions between Sitagliptin and food protein-derived DPP-IV inhibitory peptides, and between 65 binary mixtures of DPP-IV inhibitory peptides. 
Materials and methods

Reagents
40
Porcine DPP-IV (≥ 10 Units mg -1 protein), Gly-Pro-pNA, 
In silico analysis of food proteins
The occurrence of the five DPP-IV inhibitory peptides used in this study was determined in silico in 72 dietary proteins 15 10 (Supplementary Table S1 ). The sequences of the mature proteins (without the propeptide) were obtained from UniProt using the ExPASy resource portal. The occurrence of the peptides was determined using an in-house generated Matlab programme (version R2014b, MathWorks, Inc, Natick, MA, USA). Proteins 15 with the five peptides were further subjected to in silico digestion with gastrointestinal enzymes (pepsin, trypsin, chymotrypsin and elastase) using the Peptide Cutter facility in Matlab. 
DPP-IV inhibition assay
The DPP-IV inhibition assay was carried out essentially as described by Nongonierma & FitzGerald 9 . Briefly, the 45 The isobole diagrams for 50 % DPP-IV inhibition were plotted for the different Sitagliptin:peptide or binary peptide mixtures. Each isobole showed the IC 50 value for the inhibitors on the x and y axes. The line between the two IC 50 values corresponds to the line of additivity (Fig. 1C) . The concentration addition (CA) The mixture of inhibitors 1 and 2 can have an additive (CA=1), synergistic (CA < 1) or antagonistic effect (CA > 1) on DPP-IV inhibition (Fig. 1C) . The theoretical total additivity concentration 60 (Zt) of the mixture was determined as described elsewhere 17 using an in-house Matlab program. Zt corresponds to the theoritical concentration of the mixture which should yield 50 % DPP-IV inhibition if the two inhibitors have an additive effect. Zt was calculated as follows: 
Determination of the isobole diagram at 50 % DPP-IV inhibition
Statistical analysis
Means comparison was carried out with a one way ANOVA followed by a Student Newman-Keuls test using SPSS (version 22, SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. For each mixture, Zt was compared to the apparent IC 50 value 5 using a Student test (P < 0.05) as described elsewhere 12 .
Results
Occurrence of the DPP-IV inhibitory peptides in 72 dietary food proteins
The five DPP-IV inhibitory peptides studied were found within 10 50% of the dietary proteins considered (supplementary Table S1 ).
The in silico digestion of the dietary proteins predicted that 4 out of the 5 peptides may be released from 14 of the dietary proteins studied. It is interesting to note that 86% of these proteins are plant-derived. Although Trp-Pro was present within 16 of the 15 proteins studied, it was not predicted to be released by gastrointestinal enzymes ( Table 1 ). The outcome of the in silico analysis suggested that 4 of the target peptides may be released during the digestion of foods. Therefore, they may play a role in DPP-IV inhibition following oral ingestion. 
Dose-response relationship for the Sitagliptin:peptide and the binary peptide mixtures
The five DPP-IV inhibitory peptides studied were selected based on differences in their mode of inhibition and the fact that they were relatively potent food protein-derived DPP-IV inhibitors 25 (IC 50 value < 60 μM) 8, 18 . The IC 50 values obtained during this study were of the same order as previously described 8, 18 (Supplementary Table S2 ). Mixtures of Sitagliptin:peptides and binary peptides were evaluated for their ability to inhibit DPP-IV as outlined in section 2.4. The dose-response curves obtained for 30 the Sitagliptin:Trp-Lys mixtures are illustrated on Fig. 2 and that for the binary peptide mixtures Ile-Pro-Ile-Gln-Tyr:Trp-Lys are shown on Fig. 3 . A dose response relationship was seen with Sitagliptin and Ile-Pro-Ile-Gln-Tyr alone, and with all Sitagliptin:peptide and binary peptide mixtures (Fig. 2, 3 and data 35 not shown). 
Sitagliptin-peptide and peptide-peptide interactions
The 50 % isobole diagram shows the IC 50 value for Sitagliptin or 40
Ile-Pro-Ile-Gln-Tyr on the y axis and that of the peptide on the x axis ( Fig. 4 & 5) . In a few instances, the apparent IC 50 value for the mixture was close to the line of additivity for Sitagliptin:IlePro-Ile-Gln-Tyr and Sitagliptin:Trp-Pro For the other mixtures, the values were either in the area of the isobole corresponding to an antagonistic effect or in the area corresponding to a synergistic effect.
50
Most Zt values were not significantly different (P > 0.05) from the apparent IC 50 value (Table 2) 
Discussion
Confirmatory studies conducted with synthetic peptides, following mass spectrometric identification frequently show that several peptide sequences identified within active fractions of 70 food protein hydrolysates display DPP-IV inhibitory properties 5, 6, 10, 19 . This indicates that the overall DPP-IV inhibitory effect seen in food protein hydrolysates originates from a mixture of peptides rather than a single peptide. The isobole methodology has been mainly utilised to study interactive effects between 75 drugs, fertilisers, pesticides and phytochemicalsnumber of examples applied to antimicrobial peptide mixtures 20, 21 . An additive effect of Sitagliptin (when studied at one level) and peptide mixtures on DPP-IV inhibitory properties has previously been shown 11 . However, to our knowledge, study of the effect of drug-peptide and binary peptide mixtures on DPP-IV 5 inhibition has not previously been described using an isobolographic approach. The synthetic substrate, Gy-Pro-pNA, used herein for the DPP-IV inhibitory assay has a different N-terminal amino acid sequence than that of the incretins (His-Ala for GLP-1 and Tyr-Ala for 10 GIP). However, in the case of the synthetic substrate and the incretins, the presence of a Pro or Ala at position P1 is consistent with the sequence of DPP-IV preferred substrates 22, 23 . Therefore, the results described herein may be extrapolated to a physiological situation where food protein-derived peptides may 15 inhibit DPP-IV, preventing incretin degradation. Most Sitagliptin:peptide and binary peptide mixtures showed an additive effect (Table 2 and Fig. 4 & 5) . However, the Sitagliptin:Trp-Pro (1:852) mixture showed an antagonistic effect on DPP-IV inhibition. The extent of apparent IC 50 increase 20 compared to Zt was 9 % for the Sitagliptin:Trp-Pro (1:852) mixture. In the case of the Sitagliptin:Ile-Pro-Ile-Gln-Tyr (1:426 and 1:852) mixtures, a synergistic effect was seen with a reduction of the IC 50 value compared to Zt of 7 and 11 %, respectively. Although the peptides studied have different modes 25 of inhibition (competitive, non-competitive, true or substrate-type inhibitor), there did not seem to be a clear trend showing specific types of interactions in the mixtures in one instance or the other. However, it is interesting to note that, the synergistic effect was seen with a mixture of competitive DPP-IV inhibitors (Sitagliptin   30 and Ile-Pro-Ile-Gln-Tyr). While most antagonistic effects involved a non-competitive DPP-IV inhibitor (Trp-Lys and TrpPro). In addition, it was not clear why the antagonistic effect was only seen for certain ratios of the DPP-IV inhibitors studied ( Table 2) . A number of in silico approaches have suggested that Ile-Pro-Ile-Gln-Tyr behaves like a substrate type DPP-IV inhibitor 8 . This may explain the overall increase of DPP-IV inhibition seen in the Sitagliptin:Ile-Pro-Ile-Gln-Tyr (1:852 and 2:426) mixtures. Trp-Lys is an hydrophilic and positively charged peptide, while Ile-Pro-Ile-Gln-Tyr (pI 5.5) is negatively charged 5 at the assay pH (8.0). It may be possible that some electrostatic interactions between Trp-Lys and Ile-Pro-Ile-Gln-Tyr may have reduced the amount of inhibitors available for DPP-IV inhibition. Surprisingly, no antagonistic effect was seen with Trp-Arg, which has very similar characteristics to Trp-Lys. An antagonistic effect 10 was also seen in the Ile-Pro-Ile-Gln-Tyr:Trp-Leu (1:2) mixture. Both peptides are competitive DPP-IV inhibitors and compete for binding at the same site on DPP-IV. This may explain why an antagonistic effect was seen when Trp-Leu was present at the highest concentration. 15 The antagonistic activity of peptide mixtures on DPP-IV inhibition could result in the activity of specific peptides being "masked" by the presence of other peptides. This may have consequences in particular in bioassay driven fractionation approaches where specific fractions may be erroneously 20 disregarded even though they contain relatively potent DPP-IV inhibitory peptides. Similar results have been described where the immunomodulatory properties of an hydrolysate was less than that of its associated isoelectric focusing fractions when tested at the same concentration 26 . This was explained by the fact that 25 some peptides may interact through physicochemical interactions 27 , making them unavailable as bioactive components.
A well-known example of a food drug interaction is the combination of grapefruit juice and drugs. Furanocoumarin from grapefruit juice has been shown to inhibit the drug metabolising 30 enzyme, cytochrome P450 (CYP) 34A 28 . In terms of antidiabetic activity, small animal studies have demonstrated that the ingestion of Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu (β-casein f70-77, DPP-IV IC 50 = 160 μM) or a tryptic β-lactoglobulin hydrolysate containing Val-Ala-Gly-Thr-Trp-Tyr (β-lg f15-20, DPP-IV IC 50 = 35 174 μM) could lower plasma glucose following an oral glucose tolerance test 5, 6 . Recently, it was shown that a porcine skin gelatin hydrolysate could inhibit plasma DPP-IV in rats as well as reducing serum glucose in the post-prandial phase 29 . However, little or no data appears to exist on the effect of foods on the 40 pharmacokinetics of Sitagliptin in vivo following food intake 30 . There is therefore a need to evaluate the peptide sequences studied herein in humans to assess their in vivo biological activity. The interactions reported with the Sitaglitpin:peptide mixtures suggest that it may be possible to lower drug intake 45 level when combined with food protein-derived DPP-IV inhibitory peptides. This may help to reduce the possible sideeffects associated with drug intake 31 .
Conclusion
A systematic approach has been utilised to study the effect of 50
Sitagliptin:peptide and binary peptide mixtures on DPP-IV inhibition using an isobole methodology. It was shown in most cases that there was an additive effect of the mixtures on overall DPP-IV inhibition. However, in some instances antagonistic or synergistic effects were observed. Since the ability of food 55 protein-derived peptides to inhibit DPP-IV has been demonstrated in vitro, the interactive effects described herein may therefore be relevant to the post-prandial regulation of serum glucose and to the pharmacokinetics of antidiabetic drugs. In addition, the isobolographic approach used herein may aid in the 60 formulation of foods with a desired DPP-IV inhibitory profile which in turn may complement the effects of T2D preventative and therapeutic agents. In vivo studies are required to test these hypotheses.
65
Supplementary data 
